Table 3.

Genotypic and allelic frequency of the polymorphisms in patient and control group.

Allelic frequencies (N: 100)		Controls n:50	β-Thalassemia homozygous		Sickle cell anemia patients		*P value/Odds Ratio 95% CI	**P value/Odds Ratio 95% CI
			TM n:50	TI n:50	HbF ≤ 17.4% n:50	HbF > 17.4% n:50
− 158 (C → T)	C	81	59	41	5	2	0.01/2.07 (1.1–3.6)	0.29/2.4 (0.4–12.7)
	T	19	41	59	95	98
+ 25 (G → A)	G	81	60	40	5	2	0.005/2.2 (1.27–3.96)	0.29/2.4 (0.4–12.7)
	A	19	40	60	95	98
rs11886868 (C → T)	C	60	55	59	47	57	0.56/1.17 (0.67–2.06)	0.11/1.56 (0.89–2.7)
	T	40	45	41	53	43
rs7557939 (A → G)	A	38	42	43	47	36	0.88/1.04 (0.5–1.8)	0.11/1.57 (0.9–2.7)
	G	62	58	57	53	64
rs4671393 (A → G)	A	26	12	18	30	31	0.2/1.6 (0.73–3.5)	0.95/1.01 (0.55–1.85)
	G	74	88	82	70	69
rs1427407 (G → T)	G	95	96	81	89	72	0.002/5.6 (1.84–17.2)	0.003/3.14 (1.46–6.75)
	T	5	4	19	11	28
rs7606173 (G → C)	G	93	93	95	80	78	0.55/0.69 (0.21–2.28)	0.72/1.1 (0.57–2.22)
	C	07	7	5	20	22
rs66650371 TAC → 3 base Deletion	TAC	85	86	75	94	79	0.06/2.0 (0.96–4.12)	0.007/3.76 (1.4–9.8)
	–	15	14	25	6	21
rs9399137 (T → C)	T	85	86	75	94	79	0.06/2.0 (0.96–4.12)	0.007/3.76 (1.4–9.8)
	C	15	14	25	6	21

n Number of patients in each group, N Total number of alleles in each group.

*Thalassemia patients.

**SCA patients.